NCT01008332View on ClinicalTrials.gov

Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Allergy
Interventions
BIOLOGICAL

Toleromune HDM

ToleroMune HDM dose 1x4 administrations 4 weeks apart

BIOLOGICAL

Placebo

Placebo comparator, 1x4 administrations 4 weeks apart

Trial Locations (1)

Unknown

Centre de Recherche Appliqué en Allergie de Québec, Québec

Sponsors

Collaborators (1)

Adiga Life Sciences, Inc.
All Listed Sponsors
collaborator

Adiga Life Sciences, Inc.

INDUSTRY

lead

Circassia Limited

INDUSTRY

NCT01008332 - Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter